Related references
Note: Only part of the references are listed.Japanese gastric cancer treatment guidelines 2018 (5th edition)
GASTRIC CANCER (2021)
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L) 1 Antibody for Pre-treated Metastatic Gastric Cancer
Kyoko Kato et al.
ANTICANCER RESEARCH (2020)
KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
H. Yoon et al.
ANNALS OF ONCOLOGY (2020)
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Khalil Saleh et al.
EUROPEAN JOURNAL OF CANCER (2019)
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Akitaka Makiyama et al.
GASTRIC CANCER (2018)
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
Chihiro Kondoh et al.
GASTRIC CANCER (2018)
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Song Ee Park et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy
Yiyi Yan et al.
JCI INSIGHT (2018)
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Takashi Nishimura et al.
GASTRIC CANCER (2017)
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Nobuaki Mamesaya et al.
INVESTIGATIONAL NEW DRUGS (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
Gustavo Schvartsman et al.
LUNG CANCER (2017)
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
Takeshi Kawakami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
Laurence Albiges et al.
EUROPEAN JOURNAL OF CANCER (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
Kunihiro Tsuji et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Vemurafenib Sensitivity Skin Reaction after Ipilimumab
James J. Harding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo
Soroosh Radfar et al.
JOURNAL OF IMMUNOLOGY (2009)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
J. Lee et al.
ANNALS OF ONCOLOGY (2007)
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data
I Chou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
